Telix Pharmaceuticals Overview
- Founded
-
2015
- Status
-
Public
- Stock Symbol
-
TLX
- Investments
-
6
- Share Price
-
$4.51
- (As of Wednesday Closing)
Telix Pharmaceuticals General Information
Description
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
Contact Information
Primary Industry
Biotechnology
Stock Exchange
ASX
Primary Office
- 55 Flemington Road
- Suite 401
- North Melbourne, Victoria 3051
- Australia
+61 1300 000 000
Telix Pharmaceuticals Timeline
Telix Pharmaceuticals Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.51 | $4.54 | $2.46 - $5.74 | $1.43B | 317M | 907K | -$0.23 |
Telix Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 1,473,123 | 1,473,123 | 1,587,423 | 756,706 |
| Revenue | 108,035 | 108,035 | 3,674 | 3,219 |
| EBITDA | (59,945) | (59,945) | (52,565) | (28,850) |
| Net Income | (72,085) | (72,085) | (60,394) | (30,873) |
| Total Assets | 173,717 | 173,717 | 79,605 | 121,342 |
| Total Debt | 7,106 | 7,106 | 1,841 | 1,697 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Telix Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Telix Pharmaceuticals Patents
Telix Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017902209-A0 | Theranostic and/or multi-modal therapeutic radiopharmaceuticals | Inactive | 09-Jun-2017 |
Telix Pharmaceuticals Executive Team (16)
Telix Pharmaceuticals Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andreas Kluge MD | Telix Pharmaceuticals | Founder & Board Member | 000 0000 |
| Jann Skinner | Self | Board Member | 000 0000 |
| Mark Nelson Ph.D | Telix Pharmaceuticals | Board Member | 000 0000 |
Telix Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Telix Pharmaceuticals Investments & Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 13-Nov-2022 | 0000000000 | Laboratory Services (Healthcare) | 00000000 | |
| 0000000000 | 14-Dec-2020 | 0000000000 | 000.00 | Biotechnology | 000000000 |
| 0000 | 24-Dec-2018 | 0000000000 | 0000 | Distributors (Healthcare) | 000000000 |
| 00000 000000 | 11-Sep-2018 | 0000000000 | 00.00 | Biotechnology | 000000000 |
| Kyzeo Imaging | 24-Oct-2017 | Joint Venture | Other Devices and Supplies |
Telix Pharmaceuticals Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| ANMI | Distributors (Healthcare) | Liege, Belgium | 2015 |
| 000000000 | Drug Discovery | Dresden, Germany | 0000 |
Telix Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated January, 10, 2023
28.67 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 401
Rank
00.00
Percentile
